Dr. David Schnell M.D. serves as Independent Director of the Company. Dr. Schnell co-founded and has been a managing director at Prospect Venture Partners since 1997. Prior to that, Dr. Schnell served as a Partner at Kleiner Perkins Caufield & Byers, a venture capital firm. Dr. Schnell has led private investments for and served on the board of directors of numerous public and private companies. Dr. Schnell previously served on the board of directors of Amira Pharmaceuticals, Inc. (acquired by Bristol-Myers Squibb), Gloucester Pharmaceuticals (acquired by Celgene Corporation), Kythera Biopharmaceuticals, Inc. (acquired by Allergan plc) and Rinat Neuroscience Corporation (acquired by Pfizer), among others. Dr. Schnell received a B.S. in Biological Sciences from Stanford University, an M.A. in Health Services Research from Stanford University School of Medicine and an M.D. from Harvard Medical School.
As the Independent Director of Ngm Biopharmaceuticals Inc, the total compensation of David Schnell at Ngm Biopharmaceuticals Inc is 225,368$. There are 10 executives at Ngm Biopharmaceuticals Inc getting paid more, with David Woodhouse having the highest compensation of 2,092,150$.
David Schnell is 60, he's been the Independent Director of Ngm Biopharmaceuticals Inc since 2018. There are 3 older and 13 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.
David's mailing address filed with the SEC is 525 UNIVERSITY AVENUE, SUITE 1350, PALO ALTO, CA, 94301.
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over 9,159,599$ worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth 177,396,366$ . The most active insiders traders include Peter Svennilson、David V Goeddel、Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of 171,092$. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth 15,615$.
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: